This site complies with the HONcode standard for trustworthy health information:
verify here.

Rewarding for
you and us
Defeat Diabetes Foundation

Defeat Diabetes
Foundation
150 153rd Ave,
Suite 300
Madeira Beach, FL 33708

Drugs » Byetta

Search our News Articles Archives for diabetes and health news. Search by word or phrase. The latest article will appear first.

Type 2 Diabetes Drug Increases Pancreatitis and Pancreatic Cancer Risk

Posted: Wednesday, May 06, 2009

A common drug used to lower blood sugar in type 2 diabetics has been observed to increase risk of pancreatitis, and is believed to also increase long-term pancreatic cancer risk.

Once a Year Byetta in the Diabetes Pipeline

Posted: Wednesday, May 06, 2009

With Lilly/Amylin's submission of their once a week Byetta, another company, Intarcia Therapeutics, Inc., announces completion of enrollment of ITCA 650 phase 1b study for the treatment of Type 2 diabetes with their once a year dosing of Byetta.

EASD: Byetta Wins In Head to Head Trial Over Januvia In Postprandial Glucose

Posted: Wednesday, September 17, 2008

In a month-long head-to-head trial, the incretin mimetic exenatide (Byetta) reduced postprandial glucose in type 2 diabetes more than did sitagliptin (Januvia), an oral DPP-4 inhibitor, researchers reported.

New Drug Might Replace Daily Insulin Injections

Posted: Monday, September 08, 2008

For people with progressed type 2 diabetes that requires daily insulin injections, there might be a partial solution to this constant inconvenience. A new type 2 diabetes treatment has recently been developed that requires only one weekly treatment, and early results seem to indicate it is substantially effective.

Byetta May Extend Lives

Posted: Friday, August 15, 2008

According to the results of a major clinical trial, patients who took Byetta had a much lower chance of dying, about 75 percent lower, than those who took any other drug.

No Efficacy or Safety Sacrifice with Weekly Exenatide (Byetta LAR)

Posted: Friday, June 20, 2008

A long-acting version of the injectable diabetes drug exenatide (Byetta) showed efficacy advantages and safety comparable to the standard formulation given twice a day, researchers said.

Monotherapy BYETTA(R) (Exenatide) As Stand Alone Therapy

Posted: Wednesday, June 11, 2008

Submitted to FDA for Stand-Alone Therapy in Q1 2008, studies show that exenatide can lower A1c 0.7 to 0.9 points as a monotherapy.

Type 2 Patients Taking Exenatide Once Weekly Improved Glycemic Control, Weight, and Lipid Profiles

Posted: Wednesday, June 11, 2008

Amylin, Eli Lilly and Alkermes announced results from the DURATION-1 trial, a 30-week study that compared the efficacy of exenatide once weekly, a long-acting release formulation of exenatide, to BYETTA(R) (exenatide) injection.

Can Exenatide Be Substituted for Insulin?

Posted: Thursday, December 27, 2007

In the current issue of Diabetes Care, Davis et al. report on a small study exploring the safety of substituting exenatide for insulin therapy in an attempt to take patients off insulin.

Monotherapy BYETTA® Showed Significant Improvement in Glucose Control

Posted: Thursday, December 13, 2007

FDA Submission for monotherapy will be submitted in the first half of 2008.